Blended finance – philanthropy’s next frontier?
Two workshops on blended finance hosted by Convergence and supported by the Foundations Group for Impact Investing (FGII) and the Department of Foreign Affairs and Trade (DFAT) were held last week. Convergence is the global network for blended finance that aims to increase private investment in emerging markets and developing economies to advance the UN Sustainable Development Goals (SDGs) and the Paris Agreement. CEO Joan Larrea was the special guest speaker at the events. Here, DFAT’s Steph van Loon reflects on the key insights.
2024 Philanthropy Australia Conference – concurrent sessions
Recordings of the concurrent sessions of the 2024 Philanthropy Australia Conference in Adelaide, 6 and 7 August 2024.
‘Engagement and energy’ in impact investing is growing
Under the Shared Capital theme at the Philanthropy Australia conference, common themes emerged in relation to impact investment. Michelle Di Fabio, Philanthropy Australia’s Program Director, Foundations Group for Impact Investing, reflects on the key issues and discussions, the resounding increase in interest - and what’s needed for continued growth.
New conference updates! Discover speakers, panellists and more
Today we reveal a cascade of speakers! We have confirmed loads of panellists and moderators for the concurrent sessions and masterclasses. We wanted you to be the first to know.
Drumroll please… Conference program released for Adelaide 2024!
Join hundreds of your colleagues and friends for three days of inspirational ideas and insights.
Adelaide 2024 to showcase more and better giving in South Australia, Australia and beyond
The “Gather Round for philanthropy” will take place in Adelaide this August, with the centrepiece being the Philanthropy Australia Conference 2024: Shifting Perspectives, Shifting Practice running 5-7 August.
How impact investment is making a difference in global health equity
Impact investing is playing a critical and growing role in the development of medicines to treat ‘neglected diseases’ affecting the world’s poorest and most underserved peoples. These medicines would not otherwise be developed by the pharmaceutical industry, which is primarily driven by financial returns. Here, Mark Sullivan AO, founder and managing director of Medicines Development for Global Health, an Australian biopharmaceutical not-for-profit, describes how this finance model is supporting the development of Moxidectin – a potential gamechanger for the WHO’s roadmap to ending river blindness by 2030.






